Athena Philis-Tsimikas, MD

Reconsidering Standard of Care for Hypercortisolism

Video content above is prompted by the following:

For patients undergoing treatment for hypercortisolism, what are the long-term implications for glycemic control and overall health?

How might future findings from this study influence the standard of care for patients with difficult-to-control T2D?

Part 2 of this study is currently ongoing. In the meantime, how should clinicians be approaching patients who meet these criteria right now?

Videos

Panelists discuss how treating hypercortisolism in patients may have long-term effects on glycemic control and overall health, potentially influencing future standards of care for difficult-to-control Type 2 diabetes, while emphasizing the need for clinicians to carefully manage such patients as ongoing research continues.

Mifeprestone for Treatment of Hypercortisolism

•	Part 2 of the CATALYST study will assess the safety and efficacy of mifepristone treatment in patients with hypercortisolism who have difficult-to-control type 2 diabetes. Can you explain how mifepristone works to control hypercortisolism? For which patients would this treatment be appropriate?
•	The catalyst study also showed that a quarter of the patients with hypercortisolism had an adrenal tumor. What would be the best way to treat these patients?
•	Which patients would not be good candidates for surgery?

Experts discuss the CATALYST study's evaluation of mifepristone for hypercortisolism patients with hard-to-manage type 2 diabetes, its mechanism of action, suitable patient populations, treatment approaches for those with adrenal tumors, and factors determining surgical candidacy.

Spectrum of Hypercortisolism Presentations

Can you discuss the spectrum of hypercortisolism and its various clinical presentations, especially in T2D?

Based on the prevalence data from the CATALYST study, how should we approach screening of patients for hypercortisolism?

Are there specific subgroups of patients with T2D who may have a higher prevalence of hypercortisolism?

Can you talk about testing for hypercortisolism? What tests are recommended for screening and subsequent confirmation?

Can you explain the dexamethasone suppression test (DST) used in the CATALYST study?

Key opinion leaders explore the diverse clinical manifestations of hypercortisolism across its spectrum of presentations.

Engaging Primary Care Clinicians in Screening for Hypercortisolism

Why should clinicians who manage patients with diabetes, the majority of whom are in the primary care setting, care about the findings from this study?

Medical experts explore why findings from this study are crucial for clinicians managing diabetes, particularly those in primary care settings, and how these insights can impact their approach to patient care.

Athena Philis-Tsimikas, MD

Articles

Reconsidering Standard of Care for Hypercortisolism

Mifeprestone for Treatment of Hypercortisolism

Spectrum of Hypercortisolism Presentations

Engaging Primary Care Clinicians in Screening for Hypercortisolism